{"DataElement":{"publicId":"6774825","version":"1","preferredName":"Circulating Tumor Cells Positive Lymphoma Outcome Lab Percentage Value","preferredDefinition":"The value in percentage for the results of circulating tumor cells positive for lymphoma.","longName":"6774824v1.0:2180234v1.1","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"6774824","version":"1","preferredName":"Circulating Tumor Cells Positive Lymphoma Outcome","preferredDefinition":"An indication that tumor cells have been detected in a peripheral blood sample._A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas._The result of an action.","longName":"6774821v1.0:6774822v1.0","context":"Alliance","contextVersion":"1","ObjectClass":{"publicId":"6774821","version":"1","preferredName":"Circulating Tumor Cells Positive","preferredDefinition":"An indication that tumor cells have been detected in a peripheral blood sample.","longName":"C146691","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Circulating Tumor Cells Positive","conceptCode":"C146691","definition":"An indication that tumor cells have been detected in a peripheral blood sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A95D5F0-194C-2464-E053-F662850A4B1C","latestVersionIndicator":"Yes","beginDate":"2019-06-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-05","modifiedBy":"ONEDATA","dateModified":"2019-06-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6774822","version":"1","preferredName":"Lymphoma Outcome","preferredDefinition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.:The result of an action.","longName":"C3208:C20200","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lymphoma","conceptCode":"C3208","definition":"A malignant (clonal) proliferation of B- lymphocytes or T- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes Non-Hodgkin lymphomas and Hodgkin lymphomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome","conceptCode":"C20200","definition":"The result of an action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A95D5F0-195D-2464-E053-F662850A4B1C","latestVersionIndicator":"Yes","beginDate":"2019-06-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-05","modifiedBy":"ONEDATA","dateModified":"2019-06-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008547","version":"1","preferredName":"Specimen Characteristics","preferredDefinition":"attributes of a patient's laboratory sample, including the source, condition, and fixative.","longName":"SPEC_CHAR","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22908C4-638F-4A74-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A95D5F0-196E-2464-E053-F662850A4B1C","latestVersionIndicator":"Yes","beginDate":"2019-06-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-05","modifiedBy":"MORENOC","dateModified":"2020-01-08","changeDescription":"1/8/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2180234","version":"1.1","preferredName":"Lab Percentage Value","preferredDefinition":"the value as a percentage of 100.","longName":"LAB_PTG_VAL","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"5","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2008541","version":"1","preferredName":"Numbers","preferredDefinition":"the set of non-negative integers.","longName":"NUMS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B227CE66-2830-4A7B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2208119","version":"1","preferredName":"Percentage Value","preferredDefinition":"Percentage; a fraction or ratio with 100 understood as the denominator.:A numerical quantity measured or assigned or computed.","longName":"C25613:C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Percentage","conceptCode":"C25613","definition":"A fraction or ratio with 100 understood as the denominator.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-3E46-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2954D9F1-B403-0D97-E050-BB89AD435FCC","latestVersionIndicator":"Yes","beginDate":"2004-01-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2016-01-14","modifiedBy":"REEVESD","dateModified":"2016-11-23","changeDescription":"v1.1 of VD replaces v1.0 to increase overall field length and include 2 decimal places. 1.14.2016.dmr","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"% circulating malignant lymph","type":"Preferred Question Text","description":"% circulating malignant lymphoma cells","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8A95FA31-2062-2BF5-E053-F662850A98C4","latestVersionIndicator":"Yes","beginDate":"2019-06-05","endDate":null,"createdBy":"MORENOC","dateCreated":"2019-06-05","modifiedBy":"MORENOC","dateModified":"2020-01-08","changeDescription":"1/8/2020: CM Released as part of draft content review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}